[11:39] Neha Madan Seagen Entered into an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize Tivdak (tisotumab vedotin-tftv) Shots: Seagen to receive $30.0M up front
Incisive News in 3 Shots.